相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease GOLD Executive Summary
Jorgen Vestbo et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype
Jadwiga A. Wedzicha et al.
CHEST (2013)
Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro
J. Milara et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Severe asthma: future treatments
P. M. O'Byrne et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2012)
PDE4: A Novel Target in the Treatment of Chronic Obstructive Pulmonary Disease
J. M. Michalski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Selective PDE inhibitors as novel treatments for respiratory diseases
Clive P. Page et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Tetomilast: new promise for phosphodiesterase-4 inhibitors?
Stephen J. Bickston et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Phosphodiesterase inhibitors in inflammatory bowel disease
Pooneh Salari et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus
E. F. M. Wouters et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Kim Papp et al.
LANCET (2012)
Pathobiologic Mechanisms of Chronic Obstructive Pulmonary Disease
Anthony Tam
MEDICAL CLINICS OF NORTH AMERICA (2012)
Disease Progression in MRL/lpr Lupus-Prone Mice Is Reduced by NCS 613, a Specific Cyclic Nucleotide Phosphodiesterase Type 4 (PDE4) Inhibitor
Therese Keravis et al.
PLOS ONE (2012)
Therapeutic Potential of ASP3258, a Selective Phosphodiesterase 4 Inhibitor, on Chronic Eosinophilic Airway Inflammation
Miki Kobayashi et al.
PHARMACOLOGY (2012)
NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues
Issaka Yougbare et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2011)
Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease
Klaus F. Rabe
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Effects of TJN-598, a new selective phosphodiesterase type IV inhibitor on anti-Thy1 nephritis in rats
Chiharu Sadakane et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2011)
Steroid Resistance in Severe Asthma: Current Mechanisms and Future Treatment
A. Durham et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history
E. D. Bateman et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide
G. Lahu et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects
N. McCracken et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide
Gezim Lahu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
No Dose Adjustment on Coadministration of the PDE4 Inhibitor Roflumilast With a Weak CYP3A, CYP1A2, and CYP2C19 Inhibitor: An Investigation Using Cimetidine
Gabriele M. Boehmer et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
Stephen I. Rennard et al.
RESPIRATORY RESEARCH (2011)
Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects
Gail M. Gauvreau et al.
RESPIRATORY RESEARCH (2011)
Population Pharmacokinetic Modelling of Roflumilast and Roflumilast N-Oxide by Total Phosphodiesterase-4 Inhibitory Activity and Development of a Population Pharmacodynamic-Adverse Event Model
Gezim Lahu et al.
CLINICAL PHARMACOKINETICS (2010)
The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species
Rodrigo Guabiraba et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration
Richard W. Chapman et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2010)
Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways
Marie-Pierre Pruniaux et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2010)
Zl-n-91, a selective phosphodiesterase 4 inhibitor, suppresses inflammatory response in a COPD-like rat model
Ya-juan Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2010)
The preclinical pharmacology of roflumilast - A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
Armin Hatzelmann et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2010)
Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown
Miles D. Houslay
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Quinolines as a novel structural class of potent and selective PDE4 inhibitors. Optimisation for inhaled administration
Michael D. Woodrow et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury
J. Cortijo et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD
J. Vestbo et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Effect of orally administered KF66490, a phosphodiesterase 4 inhibitor, on dermatitis in mouse models
Daisuke Harada et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2009)
The Targeted Oral, Once-Daily Phosphodiesterase 4 Inhibitor Roflumilast and the Leukotriene Receptor Antagonist Montelukast Do Not Exhibit Significant Pharmacokinetic Interactions
Gabriele M. Boehmer et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
Leonardo M. Fabbri et al.
LANCET (2009)
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Peter M. A. Calverley et al.
LANCET (2009)
MECHANISMS OF DISEASE Immunologic Aspects of Chronic Obstructive Pulmonary Disease
Manuel G. Cosio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Pharmacology of a Novel, Orally Active PDE4 Inhibitor
Sunanda G. Dastidar et al.
PHARMACOLOGY (2009)
Rolipram attenuates bleomycin A5-induced pulmonary fibrosis in rats
Jin Bing Pan et al.
RESPIROLOGY (2009)
Effects of KF19514, a Phosphodiesterase 4 and 1 Inhibitor, on Bronchial Inflammation and Remodeling in a Murine Model of Chronic Asthma
Toshiyuki Kita et al.
ALLERGOLOGY INTERNATIONAL (2009)
The Efficacy and Safety of Cilomilast in COPD
Stephen Rennard et al.
DRUGS (2008)
Effect of Single and Repeated Doses of Ketoconazole on the Pharmacokinetics of Roflumilast and Roflumilast N-Oxide
Gezim Lahu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice
Piero A Martorana et al.
BMC Pulmonary Medicine (2008)
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
Diana C. Grootendorst et al.
THORAX (2007)
Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats
Richard W. Chapman et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide
Robert Hermann et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
Peter M. A. Calverley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge
C. Louw et al.
RESPIRATION (2007)
Pharmacological profile of a novel phosphodiesterase 7A and-4 dual inhibitor, YM-393059, on acute and chronic inflammation models
Satoshi Yamamoto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2006)
Efficacy and safety of roflumilast in the treatment of asthma
Eric D. Bateman et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2006)
Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma
J Bousquet et al.
ALLERGY (2006)
Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke
PA Martorana et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Roflumilast -: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease:: a randomised controlled trial
KF Rabe et al.
LANCET (2005)
Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions
E van Schalkwyk et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2005)
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells
M Mata et al.
THORAX (2005)
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers
R Barber et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease
PM Calverley et al.
EUROPEAN RESPIRATORY JOURNAL (2003)
Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease
E Gamble et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial
P Calverley et al.
LANCET (2003)
The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo
W Timmer et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2002)
分享论文
